Inhibikase Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Inhibikase Therapeutics, Inc. quarterly Income Tax Expense (Benefit) history and growth rate from Q1 2020 to Q3 2024.
  • Inhibikase Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $0.000.
Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $0 $0 Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $0 $0 Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $0 $0 Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q3 2023 $0 $0 Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $0 $0 Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $0 $0 Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q3 2022 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $0 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $0 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q1 2021 $0 $0 Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q1 2020 $0 Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.